KR20170142040A - Composition comprising fermented Poncirus trifoliata extract with antimicrobial and antiseptic activity and methods of preparation thereof - Google Patents
Composition comprising fermented Poncirus trifoliata extract with antimicrobial and antiseptic activity and methods of preparation thereof Download PDFInfo
- Publication number
- KR20170142040A KR20170142040A KR1020160075249A KR20160075249A KR20170142040A KR 20170142040 A KR20170142040 A KR 20170142040A KR 1020160075249 A KR1020160075249 A KR 1020160075249A KR 20160075249 A KR20160075249 A KR 20160075249A KR 20170142040 A KR20170142040 A KR 20170142040A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- penicillium
- fermented
- strain
- antimicrobial
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 50
- 238000000034 method Methods 0.000 title claims abstract description 16
- 239000000284 extract Substances 0.000 title claims description 94
- 230000000845 anti-microbial effect Effects 0.000 title claims description 74
- 230000002421 anti-septic effect Effects 0.000 title abstract description 6
- 235000000404 Poncirus trifoliata Nutrition 0.000 title abstract description 3
- 241001522083 Citrus trifoliata Species 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title description 4
- 241000894006 Bacteria Species 0.000 claims abstract description 68
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 64
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 33
- 238000000855 fermentation Methods 0.000 claims abstract description 33
- 230000004151 fermentation Effects 0.000 claims abstract description 33
- 239000004310 lactic acid Substances 0.000 claims abstract description 32
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 32
- 206010016952 Food poisoning Diseases 0.000 claims abstract description 14
- 208000019331 Foodborne disease Diseases 0.000 claims abstract description 14
- 239000002537 cosmetic Substances 0.000 claims abstract description 14
- 235000013305 food Nutrition 0.000 claims abstract description 12
- 241000675108 Citrus tangerina Species 0.000 claims description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- 241000228143 Penicillium Species 0.000 claims description 18
- 239000004599 antimicrobial Substances 0.000 claims description 18
- 241000588724 Escherichia coli Species 0.000 claims description 15
- 241000191967 Staphylococcus aureus Species 0.000 claims description 14
- 241000193755 Bacillus cereus Species 0.000 claims description 12
- 241000186779 Listeria monocytogenes Species 0.000 claims description 12
- 244000199885 Lactobacillus bulgaricus Species 0.000 claims description 11
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 claims description 11
- 229940004208 lactobacillus bulgaricus Drugs 0.000 claims description 11
- 241001608472 Bifidobacterium longum Species 0.000 claims description 9
- 241000607272 Vibrio parahaemolyticus Species 0.000 claims description 9
- 229940009291 bifidobacterium longum Drugs 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 claims description 8
- 229940055019 propionibacterium acne Drugs 0.000 claims description 8
- 241000607142 Salmonella Species 0.000 claims description 7
- 239000008513 turmeric extract Substances 0.000 claims description 7
- 229940052016 turmeric extract Drugs 0.000 claims description 7
- 235000020240 turmeric extract Nutrition 0.000 claims description 7
- 241000589875 Campylobacter jejuni Species 0.000 claims description 6
- 241001123663 Penicillium expansum Species 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 241000985513 Penicillium oxalicum Species 0.000 claims description 5
- 241000589876 Campylobacter Species 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 241000233866 Fungi Species 0.000 claims description 3
- 241000228150 Penicillium chrysogenum Species 0.000 claims description 3
- 240000000064 Penicillium roqueforti Species 0.000 claims description 3
- 235000002233 Penicillium roqueforti Nutrition 0.000 claims description 3
- 241001136494 Talaromyces funiculosus Species 0.000 claims description 3
- 241000590428 Panacea Species 0.000 claims description 2
- 241000186000 Bifidobacterium Species 0.000 claims 1
- 241001454293 Tetranychus urticae Species 0.000 claims 1
- 239000000645 desinfectant Substances 0.000 claims 1
- 208000002874 Acne Vulgaris Diseases 0.000 abstract description 13
- 206010000496 acne Diseases 0.000 abstract description 13
- 230000003078 antioxidant effect Effects 0.000 abstract description 10
- 208000001840 Dandruff Diseases 0.000 abstract description 8
- 239000003963 antioxidant agent Substances 0.000 abstract description 5
- 239000000419 plant extract Substances 0.000 abstract description 4
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 230000002708 enhancing effect Effects 0.000 abstract description 2
- 230000000052 comparative effect Effects 0.000 description 27
- 239000003755 preservative agent Substances 0.000 description 17
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 14
- 238000009792 diffusion process Methods 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 239000000463 material Substances 0.000 description 9
- 230000002335 preservative effect Effects 0.000 description 9
- 235000013824 polyphenols Nutrition 0.000 description 8
- 241000555688 Malassezia furfur Species 0.000 description 7
- 235000011187 glycerol Nutrition 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 150000008442 polyphenolic compounds Chemical class 0.000 description 7
- 229920001817 Agar Polymers 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 6
- 239000008272 agar Substances 0.000 description 6
- 235000013399 edible fruits Nutrition 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 244000005700 microbiome Species 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 3
- NLAWPKPYBMEWIR-SKYQDXIQSA-N (2S)-poncirin Chemical compound C1=CC(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@H]3[C@@H]([C@H](O)[C@@H](O)[C@H](C)O3)O)=CC(O)=C2C(=O)C1 NLAWPKPYBMEWIR-SKYQDXIQSA-N 0.000 description 3
- 241000131482 Bifidobacterium sp. Species 0.000 description 3
- 241000186660 Lactobacillus Species 0.000 description 3
- 241000186610 Lactobacillus sp. Species 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- NLAWPKPYBMEWIR-VGQRFNKBSA-N Poncirin Natural products O([C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1Oc1cc(O)c2C(=O)C[C@@H](c3ccc(OC)cc3)Oc2c1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1 NLAWPKPYBMEWIR-VGQRFNKBSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000607598 Vibrio Species 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000013329 compounding Methods 0.000 description 3
- 239000004744 fabric Substances 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 229940039696 lactobacillus Drugs 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000005711 Benzoic acid Substances 0.000 description 2
- 239000004342 Benzoyl peroxide Substances 0.000 description 2
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 2
- 241000238424 Crustacea Species 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 241000590002 Helicobacter pylori Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 235000019400 benzoyl peroxide Nutrition 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 235000020971 citrus fruits Nutrition 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- 150000002338 glycosides Chemical group 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229940037467 helicobacter pylori Drugs 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000009630 liquid culture Methods 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 229940075582 sorbic acid Drugs 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- 229930013915 (+)-catechin Natural products 0.000 description 1
- 235000007219 (+)-catechin Nutrition 0.000 description 1
- HFVMEOPYDLEHBR-UHFFFAOYSA-N (2-fluorophenyl)-phenylmethanol Chemical compound C=1C=CC=C(F)C=1C(O)C1=CC=CC=C1 HFVMEOPYDLEHBR-UHFFFAOYSA-N 0.000 description 1
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 1
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- 239000001606 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one Substances 0.000 description 1
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 1
- 244000291564 Allium cepa Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 241000235349 Ascomycota Species 0.000 description 1
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 240000004307 Citrus medica Species 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- 241001112695 Clostridiales Species 0.000 description 1
- 241000219130 Cucurbita pepo subsp. pepo Species 0.000 description 1
- 235000003954 Cucurbita pepo var melopepo Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 240000002045 Guettarda speciosa Species 0.000 description 1
- 235000001287 Guettarda speciosa Nutrition 0.000 description 1
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- NVNLLIYOARQCIX-MSHCCFNRSA-N Nisin Chemical compound N1C(=O)[C@@H](CC(C)C)NC(=O)C(=C)NC(=O)[C@@H]([C@H](C)CC)NC(=O)[C@@H](NC(=O)C(=C/C)/NC(=O)[C@H](N)[C@H](C)CC)CSC[C@@H]1C(=O)N[C@@H]1C(=O)N2CCC[C@@H]2C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(NCC(=O)N[C@H](C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCSC)C(=O)NCC(=O)N[C@H](CS[C@@H]2C)C(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CCSC)C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(N[C@H](C)C(=O)N[C@@H]3C(=O)N[C@@H](C(N[C@H](CC=4NC=NC=4)C(=O)N[C@H](CS[C@@H]3C)C(=O)N[C@H](CO)C(=O)N[C@H]([C@H](C)CC)C(=O)N[C@H](CC=3NC=NC=3)C(=O)N[C@H](C(C)C)C(=O)NC(=C)C(=O)N[C@H](CCCCN)C(O)=O)=O)CS[C@@H]2C)=O)=O)CS[C@@H]1C NVNLLIYOARQCIX-MSHCCFNRSA-N 0.000 description 1
- 108010053775 Nisin Proteins 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 241001263478 Norovirus Species 0.000 description 1
- 241001400472 Omiza Species 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 244000202052 Poncirus trifoliata Species 0.000 description 1
- 241001093501 Rutaceae Species 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 240000001142 Tilia japonica Species 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229940060038 chlorine Drugs 0.000 description 1
- 235000017168 chlorine Nutrition 0.000 description 1
- 229940043350 citral Drugs 0.000 description 1
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- SOROIESOUPGGFO-UHFFFAOYSA-N diazolidinylurea Chemical compound OCNC(=O)N(CO)C1N(CO)C(=O)N(CO)C1=O SOROIESOUPGGFO-UHFFFAOYSA-N 0.000 description 1
- 229960001083 diazolidinylurea Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000010200 folin Substances 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- WTEVQBCEXWBHNA-JXMROGBWSA-N geranial Chemical compound CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 description 1
- 229940107702 grapefruit seed extract Drugs 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 1
- 229940025878 hesperidin Drugs 0.000 description 1
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 1
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- ZCTXEAQXZGPWFG-UHFFFAOYSA-N imidurea Chemical compound O=C1NC(=O)N(CO)C1NC(=O)NCNC(=O)NC1C(=O)NC(=O)N1CO ZCTXEAQXZGPWFG-UHFFFAOYSA-N 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 description 1
- 229930019673 naringin Natural products 0.000 description 1
- 229940052490 naringin Drugs 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- ARGKVCXINMKCAZ-UZRWAPQLSA-N neohesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@H]3[C@@H]([C@H](O)[C@@H](O)[C@H](C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UZRWAPQLSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000004309 nisin Substances 0.000 description 1
- 235000010297 nisin Nutrition 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 208000021090 palsy Diseases 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000008858 ponciretin Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- 239000006150 trypticase soy agar Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
- A23L3/34—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals
- A23L3/3454—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals in the form of liquids or solids
- A23L3/3463—Organic compounds; Microorganisms; Enzymes
- A23L3/3472—Compounds of undetermined constitution obtained from animals or plants
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N65/00—Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
- A01N65/08—Magnoliopsida [dicotyledons]
- A01N65/36—Rutaceae [Rue family], e.g. lime, orange, lemon, corktree or pricklyash
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/02—Antioxidant
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/10—Preserving against microbes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Food Science & Technology (AREA)
- Plant Pathology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Agronomy & Crop Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Dentistry (AREA)
- Polymers & Plastics (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 탱자를 2단계로 발효시켜 항균력을 증진시킴으로써, 비브리오균(Vibrio parahaemolyticus), 황색포도상구균(Staphylococcus aureus), 살모넬라균(Salmonella enteritidis), 대장균(Escherichia coli), 캄필로박터균(Campylobacter jejuni), 리스테리아균(Listeria monocytogenes) 바실러스 세레우스(Bacillus cereus) 등 식중독균에 대해 강한 항균력을 가질 뿐 아니라 여드름균(Propionibacterium acne), 비듬균(Pityrosporum ovale) 등에 대해서도 광범위한 항균 스펙트럼을 나타내고, 장내 유익균인 유산균류(Bifidobacterium longum , Lactobacillus bulgaricus)에는 항균성이 적은 식물 추출물 조성물 및 이의 제조 방법에 관한 것이다.The present invention relates to a method for the fermentation of T. japonica in two steps to enhance the antimicrobial activity and thereby to provide a method for producing a microorganism capable of producing Vibrio parahaemolyticus , Staphylococcus aureus , Salmonella enteritidis , Escherichia coli , Campylobacter jejuni ), Listeria monocytogenes) Bacillus cereus (Bacillus cereus), etc., as well as have a strong antibacterial activity against bacteria sikjungdokgyun acne (Propionibacterium acne), bideumgyun (Pityrosporum ovale ), etc., and exhibits a broad spectrum of antibacterial activity against bacteria such as lactic acid bacteria ( Bifidobacterium longum , Lactobacillus bulgaricus ), and a method for producing the same.
소득 수준이 향상되면서 위생관념이 철저해지고 있는 추세이나 식중독 사고는 여전히 전세계적으로 주요 사망 원인이 되고 있다. 식중독 발생 추이를 살펴보면 최근에는 계절에 관계없이 연중 발생하며, 특히 겨울철에도 환자수가 줄어들지 않고 있다. 여름철에는 주로 살모넬라, 황색포도상구균, 장염 비브리오균 등의 다양한 원인균이 검출되고, 10-12월의 겨울철에도 노로바이러스와 함께 다양한 원인균 등이 다수 검출되는 추세이다. 따라서 최근 식약처에서도 식품내 유해 미생물에 대한 규격을 더욱 강화하고 있으며 항균 보존제의 역할이 더욱 중요시 되고 있다. As income levels have improved, the hygiene concept has become more thorough, but food poisoning accidents are still the leading cause of death worldwide. Looking at the trends of food poisoning, the number of patients has not decreased in recent years, especially in winter, regardless of the season. In summer, various causative bacteria such as Salmonella, Staphylococcus aureus, and Vibrio parahaemolyticus are detected, and many causative bacteria such as Norovirus are detected in winter in October and December. Therefore, recently, the standard of harmful microorganisms in foods is further strengthened and the role of antimicrobial preservative is becoming more important.
또한 화장품, 생활용품 분야에서도 미생물에 오염된 제품은 성분의 변질에 따른 기능저하는 물론 피부 발진, 염증등 피부 트러블과 미생물 감염의 위험성을 가지며, 화장품 제품의 특성상 사용기간이 수개월에서 수년까지 길기 때문에 항균 보존제의 역할은 매우 중요하다. 더욱이 여드름균, 비듬균 등에 의한 피부 트러블을 위해서는 이들을 억제할 수 있는 여러 성분들이 사용되고 있다. In cosmetics and household products, products contaminated with microorganisms have a risk of skin troubles and microbial infections such as skin rashes and inflammation as well as deterioration of functions due to deterioration of ingredients, and the period of use is long from several months to several years due to the characteristics of cosmetic products The role of antimicrobial preservatives is very important. Furthermore, various ingredients that can inhibit them are used for skin troubles caused by acne bacteria and dandruff.
식품에서 항균, 방부제는 그 편의성과 비용 때문에 benzoic acid, nitrite, sorbic acid, sodium metabisulfite, 염소제 등 다양한 합성 보존료가 장기간 사용되어 왔다. 또 현재 화장품이나 생활용품에서도 paraben류 (ester of hydroxybenzoic acid), phenoxyethanol, imidazolidinyl urea, diazolidinyl urea, sorbic acid, triclosan 등의 합성 성분들이 단독 또는 혼합으로 사용되어 왔고, 또 별도로 여드름균, 비듬균 등을 억제하기 위해서는 salicylic acid, benzoyl peroxide 등이 사용되어 왔다. A variety of synthetic preservatives such as benzoic acid, nitrite, sorbic acid, sodium metabisulfite and chlorine have been used for a long time because of their convenience and cost. In addition, cosmetic products and daily necessities have been used either alone or as a mixture of parabens, phenoxyethanol, imidazolidinyl urea, diazolidinyl urea, sorbic acid and triclosan, and they also inhibit acne and dandruff Salicylic acid, benzoyl peroxide, and the like have been used.
이러한 합성 항균 보존제들은 사용이 간편하고 항균, 방부 효과가 우수하기 때문에 대부분의 식품, 화장품과 생활용품에서 사용되고 있으나, 최근 합성 방부제의 각종 문제점 및 부작용이 밝혀지면서 지나치게 광범위한 사용 및 과다한 사용 등의 위험성이 대두되고 있다. 인공 항균 보존제의 문제점으로는, ①피부 자극 또는 알러지 유발 ②암 유발 가능성 (유방암 조직에서 방부성분 검출), ③남성생식력 약화, 여성호르몬 역할 (방부제 관련 연구 다수), ④이외에 중추신경 마비, 유전자변이 유발 등에 대한 가능성이 우려되고 있어 WHO 등에서도 부작용의 위험성을 경고하고 있다. These synthetic antimicrobial preservatives are used in most foods, cosmetics and daily necessities because they are easy to use and have excellent antimicrobial and antiseptic effect. However, since various problems and side effects of synthetic preservatives have been disclosed, risks of overuse and overuse Is emerging. The problems of the artificial antimicrobial preservative include ① skin irritation or allergen induction ② possibility of cancer (detection of preservative component in breast cancer tissue), ③ weakening of male reproductive power, role of female hormone (many studies related to preservatives), ④ central nerve palsy, And WHO also warns of the danger of side effects.
수십년간 사용되어온 인공 항균, 방부제가 이런 잠재적 위험성을 갖고 있어, 기존과 다른 종류의 항균, 방부제를 도입하거나 또는 천연에 존재하는 물질 중에서 항균이나 방부 효과를 갖는 물질을 찾아내는 연구가 활발히 진행되고 있다. 천연물에 함유된 succinic, malic, tartaric, benzoic acid 등의 유기산류의 미생물 증식억제작용과 flavonoids, catechin 류의 항균효과가 연구되었으며, 동식물의 조직에 함유된 탄소수 12-18개의 지방산이 효과적인 항균성 물질로 보고되었고, 계란에 함유된 lysozyme, transferrin과 우유에 함유된 lactoferrin, 젖산균이 생성하는 nisin 등의 단백질성 물질이 알려져 있다. 또 우리나라에서 많이 사용되는 향신료인 마늘과 양파의 성분에 의한 항균작용이 연구되었으며, 국내의 다양한 생약재 또는 식물성분에 의한 항균성에 대한 연구가 진행되어, 산사, 황련, 측백, 창출, 석창포의 ethanol 추출물이 그람양성 및 음성세균 모두에 대하여 강한 항균성을 가졌다고 보고되었으며, 상백피 추출물이 Listeria monocytogenes 증식을 저해하는 것으로 보고되었고, 한약재인 오미자, 울금, 자초, 고삼, 감초 등이 항균활성이 있다고 보고되었다. Artificial antimicrobials and preservatives, which have been used for decades, have such potential hazards, and researches have been actively conducted to introduce antimicrobial and preservative agents that are different from conventional ones, or to find substances having antimicrobial or preservative effects in natural substances. Antioxidative activities of organic acids such as succinic, malic, tartaric and benzoic acid in natural products and antimicrobial effects of flavonoids and catechins have been studied. The fatty acids of 12-18 carbon atoms contained in plant and animal tissues are effective antimicrobial substances It has been reported that lysozyme contained in eggs, transferrin and lactoferrin contained in milk, and nisin produced by lactic acid bacteria are known. The antimicrobial activity of garlic and onion has been studied in Korea and various antimicrobial activities of various herbal medicines or plant ingredients have been studied in Korea. It has been reported that the extracts of L. monocytogenes inhibit the proliferation of Listeria monocytogenes , and the medicinal herbs such as Omiza, Ulgum, Sacho, Gosam and Licorice have antimicrobial activity.
그러나 대부분의 천연 항균 보존료는 합성 보존료에 비해 항균 spectrum 이 작고 항균력이 약해 광범위하게 사용되기 어려운 실정이다. 최근 자몽씨 추출물 등 일부 성분을 이용한 제품이 있으나 주로 해외 원료를 수입하여 사용하고 있으며 국내 제품은 극히 적어, 안전하고 강력하면서도 광범위하고 경제적으로 사용할 수 있는 천연 항균 보존료의 개발은 국내 뿐 아니라 해외 시장 확보도 원활이 할 수 있을 것으로 기대한다. However, most natural antimicrobial preservatives have a smaller antimicrobial spectrum and weaker antimicrobial activity than synthetic preservatives. Recently, we have been using some ingredients such as grapefruit seed extract, but we are mainly importing and using foreign raw materials. The domestic products are very few, and the development of natural antimicrobial preservative that can be used safely, We expect that it will be smooth.
본 발명자들은 천연물 유래의 항균 소재를 찾아내고 항균력을 증진시킬 수 있는 방법을 연구하던 중, 국내에서 자생하는 식물 종인 탱자가 식중독균에 대해 항균 및 방부 활성이 우수한 것을 확인하고, 특히 이를 2단계로 발효하여 항균성분들의 형성 및 추출을 극대화 함으로써 더욱 항균력이 강하고 항균 스펙트럼 범위가 넓은 활성을 갖는 식물 추출물을 개발하게 되었다.The inventors of the present invention have studied antibacterial materials derived from natural materials and studied methods for enhancing the antibacterial ability, and have found that tangerine, a native plant species in Korea, has excellent antibacterial and antiseptic activities against food poisoning bacteria, Thereby maximizing the formation and extraction of antimicrobial components, thereby developing a plant extract having a strong antimicrobial activity and a broad antimicrobial spectrum range.
본 발명의 목적은 항균력이 증진된 천연물 유래의 항균소재를 개발하는 것이다. 보다 상세하게는 비브리오균(Vibrio parahaemolyticus), 황색포도상구균(Staphylococcus aureus), 살모넬라균(Salmonella enteritidis), 대장균(Escherichia coli), 캄필로박터균(Campylobacter jejuni), 리스테리아균(Listeria monocytogenes), 바실러스 세레우스(Bacillus cereus) 등 식중독균에 대해 강한 항균력을 가질 뿐 아니라 여드름균(Propionibacterium acne), 비듬균(Pityrosporum ovale) 등에 대해서도 광범위한 항균 스펙트럼을 나타내고, 장내 유익균인 유산균류(Bifidobacterium longum , Lactobacillus bulgaricus)에는 항균성이 적어 각종 식품뿐 아니라 화장품, 의약품, 농약 또는 생활용품에 적용이 가능한 증진된 항균력을 가지는 조성물과 제조방법, 그리고 이의 용도를 제공하는 것이다.It is an object of the present invention to develop an antibacterial material derived from a natural product with enhanced antibacterial activity. More specifically, the bacterium Vibrio (Vibrio parahaemolyticus), Staphylococcus aureus (Staphylococcus aureus), Salmonella (Salmonella enteritidis), E. coli (Escherichia coli ), Campylobacter jejuni), Listeria monocytogenes (Listeria monocytogenes), Bacillus cereus (Bacillus cereus), etc., as well as have a strong antibacterial activity against bacteria sikjungdokgyun acne (Propionibacterium acne), bideumgyun (Pityrosporum ovale ), etc., and exhibits a broad spectrum of antibacterial activity against bacteria such as lactic acid bacteria ( Bifidobacterium longum , Lactobacillus bulgaricus ) have a reduced antimicrobial activity, as well as various foods, cosmetics, medicines, pesticides or household products, and a method for producing the same.
상기한 목적을 위하여 본 발명이 제 1 의 형태는 페니실리움 균주에 의해 발효된 탱자 추출물을 포함하는 항균 조성물, 또는 유산균 균주에 의해 발효된 탱자 추출물을 포함하는 항균 조성물, 또는 페니실리움 균주 및 유산균 균주에 의해 2단 발효된 탱자 추출물을 포함하는 항균 조성물이다.For the above-mentioned object, the first aspect of the present invention is an antimicrobial composition comprising a turmeric extract fermented by a strain of Penicillium, or an antimicrobial composition comprising a turmeric extract fermented by a lactic acid bacterial strain, The antimicrobial composition according to any one of claims 1 to 7, wherein the extract is a two-stage fermented product.
상기 탱자는 이에 제한 되는 것은 아니나 생탱지, 지실, 지각으로 이루어진 그룹에서 선택된 어느 하나 일 수 있다. 상기 페니실리움 균주는 Penicillium oxalicum , Penicillium expansum , Penicillium funiculosum, Penicillium chrysogenum , Penicillium glaucum , 및 Penicillium roqueforti 으로 이루어진 그룹에서 선택된 어느 하나 이상의 균주일 수 있다. 상기 유산균은 비피도박테리움 롱검(Bifidobacterium longum)을 포함하는 비피도박테리움 속(Bifidobacterium sp) 균주 및 락토바실러스 불가리쿠스(Lactobacillus bulgaricus)로 이루어진 그룹에서 선택된 어느 하나 이상의 유산균일 수 있다. 상기 균은 이에 제한 되는 것은 아니나 비브리오균(Vibrio parahaemolyticus), 황색포도상구균(Staphylococcus aureus), 살모넬라균(Salmonella enteritidis), 대장균(Escherichia coli), 캄필로박터균(Campylobacter jejuni), 리스테리아균(Listeria monocytogenes), 바실러스 세레우스(Bacillus cereus)의 식중독균에 항균활성을 나타내는 균 또는 프로피오니박테리움 아크네(Propionibacterium acne), 비듬균인 피티로스포룸 오발(Pityrosporum ovale)의 피부 상재 트러블성 균이다. The tangerine may be any one selected from the group consisting of raw tangerine, filaments, and crustaceans, without being limited thereto. The Penicillium strain is Penicillium oxalicum , Penicillium expansum , Penicillium funiculosum, Penicillium chrysogenum , Penicillium glaucum , and Penicillium roqueforti , And the like. The lactic acid bacteria may be any one or more lactic acid bacteria selected from the group consisting of Bifidobacterium sp. And Lactobacillus bulgaricus including Bifidobacterium longum . Such bacteria include, but are not limited to, Vibrio parahaemolyticus), Staphylococcus aureus (Staphylococcus aureus), Salmonella (Salmonella enteritidis), E. coli (Escherichia coli ), Campylobacter ( Bacillus cereus ), which exhibit antimicrobial activity against bacteria or Propionibacterium acne, and Pityrosporum ovale , which is an antimicrobial agent of the genus Lactobacillus, such as Lactobacillus sp. jejuni , Listeria monocytogenes , Bacillus cereus , It is sexually transmitted.
상기 조성물은 발효된 탱자 추출물을 0.1 내지 50 중량%로 포함하는 식품, 화장품 또는 스프레이 살균제인 항균 조성물일 수 있다.The composition may be an antimicrobial composition which is a food, cosmetic or spray sterilizing agent containing 0.1 to 50% by weight of fermented turmeric extract.
본 발명의 제 2 의 형태는 탱자 추출물을 페니실리움으로 발효하여 제조하는 것을 특징으로 하는 항균 조성물 제조방법이다. 바람직하게는 상기 탱자 추출물의 건조중량 기준으로 1:1 ~ 1: 0.1의 비율로 물을 가하는 단계 및, 상기 물이 가하여진 탱자 추출물에 전배양한 페니실리움 균주를 접종하여 15 ~ 30 ℃에서, 1 ~ 10 일 동안 발효하여 제조될 수 있다. 상기 탱자 및 균에 대한 설명은 본 발명의 제 1 의 형태의 설명을 참조한다.A second aspect of the present invention is a method for producing an antimicrobial composition, which comprises fermenting a panacea extract with Penicillium. Preferably, water is added at a ratio of 1: 1 to 1: 0.1 based on the dry weight of the panther extract, and the Penicillium strain pre-cultured in the water extract-added panther extract is inoculated at 15 to 30 ° C , And fermenting for 1 to 10 days. The description of the tangerine and the bacteria refers to the description of the first aspect of the present invention.
본 발명의 제 3 의 형태는 탱자 추출물을 유산균으로 발효하여 제조하는 것을 특징으로 하는 항균 조성물 제조방법이다. 바람직하게는 상기 탱자 추출물의 건조중량 기준으로 1:1 ~ 1: 10의 비율로 물을 가하는 단계 및, 상기 물이 가하여진 탱자 추출물에 전배양한 유산균 균주를 접종하여 15 ~ 40 ℃에서, 0.5 ~ 5 일 동안 발효하여 제조될 수 있다. 상기 탱자 및 균에 대한 설명은 본 발명의 제 1 의 형태의 설명을 참조한다.A third aspect of the present invention is a method for producing an antimicrobial composition, which comprises fermenting a tuna extract with lactic acid bacteria. Preferably, the step of adding water at a ratio of 1: 1 to 1:10 on the dry weight basis of the extract of Tanganyong, and a step of inoculating a lactic acid bacterium strain pre-cultured in the extract of Tang which is added with water, ~ 5 days after fermentation. The description of the tangerine and the bacteria refers to the description of the first aspect of the present invention.
본 발명의 제 4 의 형태는 탱자 추출물을 페니실리움으로 발효시킨 후, 2단계로 유산균으로 발효하여 제조하는 것을 특징으로 하는 항균 조성물 제조방법이다. 바람직하게는 상기 탱자 추출물의 건조중량 기준으로 1:1 ~ 1: 0.1의 비율로 물을 가하는 단계 및, 상기 물이 가하여진 탱자 추출물에 전배양한 페니실리움 균주를 접종하여 15 ~ 30 ℃에서, 1 ~ 10 일 동안 1차 발효하는 단계; 상기 1차 발효물에 1:1 ~ 1: 10의 비율로 비율로 물을 가하는 단계; 및 상기 물이 가여진 1차 발효물에 전배양한 유산균 균주를 접종하고, 15 ~ 40 ℃, 0.5 ~ 5 일 동안 2차 발효하여 제조되어질 수 있다. 상기 탱자 및 균에 대한 설명은 본 발명의 제 1 의 형태의 설명을 참조한다.In a fourth aspect of the present invention, there is provided a method for producing an antimicrobial composition, which comprises fermenting an Angelica gigantea extract with Penicillium and then fermenting it with lactic acid bacteria in two steps. Preferably, water is added at a ratio of 1: 1 to 1: 0.1 based on the dry weight of the panther extract, and the Penicillium strain pre-cultured in the water extract-added panther extract is inoculated at 15 to 30 ° C , Primary fermentation for 1 to 10 days; Adding water to the primary fermentation product at a ratio of 1: 1 to 1:10; And inoculating the lactic acid bacteria strain pre-cultured in the primary fermented product to which the water has been added, followed by secondary fermentation at 15 to 40 ° C for 0.5 to 5 days. The description of the tangerine and the bacteria refers to the description of the first aspect of the present invention.
본 발명에 따른 항균 조성물 제조방법은 이에 추가적인 공정을 포함할 수 있다. 즉 여과하는 단계이거나, 침전시키는 단계, 정제하는 단계 등을 추가적으로 포함할 수 있다. The method for producing an antimicrobial composition according to the present invention may include an additional step. That is, filtration, precipitation, purification, and the like.
본 발명에 따른 식물 추출물을 포함하는 조성물은 다양한 식중독균들과 피부 상재균에 대해 폭넓은 항균 스펙트럼을 나타내고, 항산화능이 우수하다. 이러한 조성물은 식품 조성물에 적용이 가능하며, 이외에도 화장품, 의약품 및 생활용품 등의 다양한 분야에서 항균, 방부, 살균 목적으로 유용하게 이용가능하다.The composition containing the plant extract according to the present invention exhibits a broad spectrum of antimicrobial activity against various food poisoning bacteria and skin-damaging bacteria and has excellent antioxidant ability. Such a composition can be applied to food compositions, and is also useful for various purposes such as cosmetics, medicines and daily necessities for antibacterial, antiseptic, and sterilizing purposes.
도 1은 확산법에 의한 측정된 대장균에 대한 항균 활성을 보여 준다. 실시예 1, 2, 3, 4에서 제조된 추출물과 무처리군, 대조군(paraben)의 사진이다. A: 실시예 1 추출물; B: 실시예 2 추출물; C: 실시예 3 추출물; D: 실시예 4 추출물.Figure 1 shows the antimicrobial activity against E. coli measured by the diffusion method. The photographs of the extracts prepared in Examples 1, 2, 3 and 4, the non-treated group and the control group (paraben). A: Extract of Example 1; B: Example 2 extract; C: Example 3 extract; D: Example 4 Extract.
탱자는 운향과(Rutaceae)에 속하는 낙엽관목인 탱자나무 (Poncirus trifoliata Rafinesque)의 과실로 4∼5월에 개화하며 과실은 10월에 황색으로 착색되고 특유의 향기를 지니고 있으나 강한 신맛으로 귤이나 오렌지, 레몬과 같이 생용 하기에는 부적합하다. 한국과 중국을 포함한 동남아시아에서는 미성숙된 탱자를 지실(枳實)이란 명칭의 한약재로 사용하고 있으며, 완숙된 탱자의 껍질만 말린 것을 지각(枳殼)이라 한다. 탱자나무 속 식물의 과실은 약용으로 사용되어 왔으며 지실은 습진 치료제로 쓰고, 지각은 설사 치료제 및 관장에 사용하였다. 이밖에도 건위제나 소화불량, 자궁하수, 내장이완 등에도 사용하였으며, 최근에는 아토피와 구강치료제로 사용 되고 있다. Tazza is a deciduous shrub belonging to the genus Rutaceae ( Poncirus trifoliata Rafinesque) is bloomed in April to May. Fruit is colored yellow in October and has a unique scent, but with a strong acidity, it is not suitable for tangerine, orange or lemon. In South and Southeast Asia, including Korea and China, immature tangerine is used as herbal medicines, called 枳实, and dried shells of ripe tangerine are called crust. Fruit of tangerine plants has been used for medicinal purposes, while fungus has been used for eczema treatment, and crust has been used for diarrhea treatment and enema. In addition, it has been used to treat dryness, digestion, uterine drainage, and internal relaxation. Recently, it has been used for atopic and oral treatment.
탱자열매의 주요성분으로는 hesperidin, neohesperidin, naringin 및 cumalin류, terpene류, 정유성분 등이 보고되었으며(Park and Chun, 1969; Oh et al., 1989; Chung et al., 2004). 이러한 성분들과 생체기능과의 상관성에 대해 많은 연구가 수행되고 있다.(Patkar et al., 1979, Fewtrell et al., 1982; Sagi-Eisenberg et al., 1985; Kanemoto et al., 1993; Lee et al., 1996; Lee et al., 2005). The major components of tangerine fruit were hesperidin, neohesperidin, naringin and cumalin, terpenes and essential oils (Park and Chun, 1969; Oh et al., 1989; Chung et al., 2004). A number of studies have been conducted on the relationship between these components and biofunctions (Patkar et al., 1979, Fewtrell et al., 1982; Sagi-Eisenberg et al., 1985; Kanemoto et al. et al., 1996; Lee et al., 2005).
탱자의 항균성에 관한 특허로는, 등록특허 10-1399695에 항생제 내성 균주에 대하여 항균 활성을 나타내는 것을 특징으로 하는 탱자추출 조성물에 대한 것과 등록특허 10-1346412에 비듬균 또는 무좀균에 대한 항진균 활성을 가지는 것을 특징으로 하는 탱자추출 조성물이 있으나, 각각 단순추출물을 특정용도에 대한 것으로만 주장하고 있고, 등록특허 10-0526992에 물추출물에 유산균과 효소를 이용해 만든 헬리코박터 억제기능의 탱자추출발효물, 등록특허 10-0322876 에 지실에서 추출정제된 poncirin에 장내세균 플로라를 배양해 ponciretin을 형성시킨 헬리코박터 억제기능의 추출물 등이 있으나, 한정된 조건에서의 유산균발효 및 헬리코박터라는 균억제 용도에 한정하고 있다. 상기 탱자 추출물들은 특정적 용도로는 사용할 수 있겠으나 식품, 화장품 등에 상업적으로 사용할 수 있는 광범위하고 강력한 방부 또는 항균제로 사용하기는 어려운 것으로 여겨진다. Patent patents relating to antimicrobial activity of a tangerine include patent application No. 10-1399695, which discloses antibacterial activity against antibiotic resistant strains, and those having antibacterial activity against Streptococcus or Ascomycetes in Patent No. 10-1346412 The present invention relates to a fermented product obtained by extracting tangerine from a fermented product of Helicobacter pylori which is produced by using lactic acid bacterium and enzyme as a water extract in the registered patent 10-0526992, -0322876, extracts of poncirin, poncirin, and poncirin to form ponciretin. However, it is limited to lactic acid bacteria fermentation and Helicobacter pylori inhibition under limited conditions. The above-mentioned extracts can be used for specific purposes, but it is considered that they are difficult to be used as a broad and powerful preservative or antimicrobial agent which can be used commercially in foods, cosmetics and the like.
한편, 탱자와 같은 운향과 식물들, 즉 감귤, 유자, 오렌지, 자몽 등의 과실은 두꺼운 과피를 가지고 있어 과육을 보호하며, 대부분의 생리활성, 항균 성분인 terpinoid, polyphenol, flavonoid, alkaloid 류 들은 주로 과피에 존재한다. 특히 많은 polyphenol, flavonoid 류는 저장형인 배당체(glycoside) 형태로 존재하며 외부 자극이나 감염시에 활성형인 비당체(aglycone) 형태로 전환하는 경우가 많다. 이에 본 발명자들은 탱자의 항균 성분들이 두터운 과피의 cellulose, pectin 등 고분자 다당 성분들에 의해 잘 용출되지 않으며, 대부분 배당체 형태로서 활성형이 적어 항균성도 약하다는 것을 발견하고, 이를 개선할 경우 기존의 단순한 물추출, 알코올 등의 용매 추출에 의한 것보다 강한 항균력을 나타낼 뿐 아니라 기존보다 광범위한 항균 스펙트럼을 나타내어 다양하게 사용할 수 있음을 확인하여 본 발명을 완성하게 되었다. 즉 본 발명자들은 이들 탱자 재료에 먼저 페니실리움(Penicillium) 속 균주를 이용하여 고상 발효시키고 이어서 이 발효물에 유산균을 액상 발효시키는 2단계 발효과정을 통하면 항균 및 방부능이 더욱 향상되는 것을 확인하였다.On the other hand, fruits such as tangerine and citrus fruits such as citrus, citron, orange, and grapefruit have thick peels and protect the pulp. Most of the physiological activity, antibacterial components such as terpinoid, polyphenol, flavonoid and alkaloids It is present in the skin. Especially, many polyphenols and flavonoids are stored in glycoside form and are often converted to aglycone form which is active during external stimulation or infection. Accordingly, the present inventors have found that antimicrobial components of tangerine are hardly eluted by polymeric polysaccharide components such as thick cellulose, pectin, and most of them are glycoside forms, Water extraction, alcohol, etc., as well as exhibiting a broader antimicrobial spectrum than the conventional ones, and thus it can be used in various ways, thus completing the present invention. In other words, the inventors of the present invention have found that the antimicrobial and antimicrobial activity is further improved through the two-step fermentation process in which the fermented product is first fermented by using a strain of the genus Penicillium in the tangerine material, followed by fermentation of the fermented product with lactic acid bacteria .
본 발명의 탱자 발효는 어린 건조 탱자인 지실, 완숙 탱자 과피인 지각 및 생탱자를 모두 사용할 수 있다. The tangerine fermentation of the present invention can be used as a young dry tangerine, a zucchini tangerine crust, and a living creature.
1차 발효로서, 발효균인 페니실리움 균주는 윤향과 과실의 과피를 분해하는 것이면 크게 그 종류를 한정하지 않으며, Penicillium oxalicum , Penicillium expansum , Penicillium funiculosum , Penicillium chrysogenum, Penicillium glaucum , Penicillium roqueforti 등을 사용할 수 있다. 탱자는 건조중량 기준으로 1:1 ~ 1: 0.1의 비율, 바람직하게는 1: 0.5 의 비율로 물을 가하여 물을 흡수한 상태로 만들고 미리 전배양한 페니실리움 균주를 접종하여 고상 발효시킨다. 발효는 15 ~ 30 ℃, 바람직하게는 25 ℃에서 진행하며, 1 ~ 10 일, 바람직하게는 3 일 정도 발효 시킨다. 발효가 끝난 발효물은 멸균 및 혼합을 진행한다. As the primary fermentation, the strain of Penicillium which is a fermenting microorganism does not limit its kind to that which decomposes the perilla of the fruit and fruit, and Penicillium oxalicum , Penicillium expansum , Penicillium funiculosum , Penicillium chrysogenum, Penicillium glaucum , Penicillium roqueforti Etc. may be used. The tangerine is water-added in a ratio of 1: 1 to 1: 0.1 on a dry weight basis, preferably in a ratio of 1: 0.5, and the solid is fermented by inoculating the pre-cultivated Penicillium strain. The fermentation is carried out at 15 to 30 캜, preferably 25 캜, and fermentation is performed for 1 to 10 days, preferably about 3 days. Fermented fermented products are sterilized and mixed.
2차 발효로서, 발효물은 중량 기준으로 1: 1 1:1 ~ 1: 10의 비율, 바람직하게는 1: 3 의 비율로 물을 가하여 미리 전배양한 유산균 균주를 접종하여 액상 발효시킨다. 발효는 15 ~ 40 ℃, 바람직하게는 30 ℃에서 진행하며, 0.5 ~ 5 일, 바람직하게는 1 일 정도 발효 시킨다. 발효가 끝난 발효물은 멸균 및 혼합을 진행한다. 이때 발효균주인 유산균은 크게 종류를 한정하지는 않으나, 사람이나 동물의 장내에서 유익한 균주로 알려진 비피도박테리움 롱검(Bifidobacterium longum)을 포함하는 비피도박테리움 속(Bifidobacterium sp) 균주, 락토바실러스 불가리쿠스(Lactobacillus bulgaricus)를 포함하는 락토바실러스 속(Lactobacillus sp.) 균주가 효과적이다.As the secondary fermentation, the fermented product is inoculated with the lactic acid bacterial strain pre-preincubated with water at a ratio of 1: 1 1: 1 to 1:10, preferably 1: 3, on a weight basis and fermented in liquid phase. Fermentation is carried out at 15 to 40 캜, preferably 30 캜, and fermentation is performed for 0.5 to 5 days, preferably about 1 day. Fermented fermented products are sterilized and mixed. At this time, the lactic acid bacteria which are the host of the fermenting bacteria are not limited to a large variety, but include strains of Bifidobacterium sp., Bifidobacterium sp., Lactobacillus bulgaricus, Bifidobacterium longum , Lactobacillus sp. ) Containing Lactobacillus bulgaricus is effective.
2단계 발효에 의해 제조된 발효물은 다음의 정제 방법을 적용하여 정제 할 수 있다. 즉, 발효물은 여과후 흡착수지(adsorption resin) 등을 이용하여 활성성분들을 흡착후 용리함으로써 농축 시키거나, 여과후 농축한 뒤 물을 가하고 냉각함으로써 수용성이 낮은 활성성분들을 침전시키는 방법으로 항균 활성을 갖는 성분들을 정제 및 농축할 수 있다. 회수된 추출물은 통상의 방법으로 건조하거나, 식품용은 20 ~ 90%의 glycerin 수용액, 화장품용은 20 ~ 90%의 1,3-butylene glycol 수용액 등과 같은 폴리올(polyol) 수용액에 용해하여 사용할 수 있다.The fermented product produced by the two-stage fermentation can be purified by applying the following purification method. That is, the fermented product is obtained by filtering the active components after filtration and then concentrating them by adsorption, followed by concentration by filtration, followed by concentration with water, followed by cooling, thereby precipitating active ingredients with low water solubility. ≪ / RTI > can be purified and concentrated. The recovered extract can be dried by a conventional method or dissolved in a polyol aqueous solution such as glycerin aqueous solution of 20 to 90% for food and 20 to 90% of 1,3-butylene glycol aqueous solution for cosmetics .
본 발명에 따른 조성물은 다양한 미생물, 특히 식중독 균에 광범위한 항균 활성을 나타낸다. 구체적으로, 상기 조성물은 비브리오균(Vibrio parahaemolyticus), 황색포도상구균(Staphylococcus aureus), 살모넬라균(Salmonella enteritidis), 대장균(Escherichia coli), 캄필로박터균(Campylobacter jejuni), 리스테리아균(Listeria monocytogenes), 바실러스 세레우스(Bacillus cereus) 등 식중독균에 대해 강한 항균력을 나타내었고, 여드름균인 프로피오니박테리움 아크네(Propionibacterium acne), 비듬균인 피티로스포룸 오발(Pityrosporum ovale)과 같은 피부 상재 트러블성 균에 대해서도 항균활성을 나타내어 보다 광범위한 항균 스펙트럼을 나타내었다. The composition according to the present invention exhibits a wide range of antibacterial activity against various microorganisms, especially food poisoning bacteria. Specifically, the composition parahaemolyticus (Vibrio parahaemolyticus), Staphylococcus aureus (Staphylococcus aureus), Salmonella (Salmonella enteritidis), E. coli (Escherichia coli ), Campylobacter The bacteria showed a strong antibacterial activity against food poisoning bacteria such as Jejuni, Listeria monocytogenes and Bacillus cereus . Propionibacterium acne , Pityrosporum ovale , And also exhibited a broader antimicrobial spectrum.
또한 상기 조성물은 장내 유익균인 유산균류(Bifidobacterium longum , Lactobacillus bulgaricus)에는 상대적으로 적은 항균 활성을 나타내었다.In addition, the above-mentioned composition is useful as a beneficial bacteria in the intestines, such as Bifidobacterium longum , Lactobacillus bulgaricus ) showed relatively low antimicrobial activity.
이하 실시예와 실험예를 통하여 본 발명의 내용을 설명하나 본 발명이 이에 국한하는 것은 아니다.Hereinafter, the present invention will be described with reference to Examples and Experimental Examples, but the present invention is not limited thereto.
비교예Comparative Example 1: 탱자의 단순 1: Tanga's simplicity 열수Heat number 추출물 제조 Extract preparation
재료는 건조된 완숙 탱자인 지각을 사용하였다. 재료 100g에 건조중량대비 10배수 물을 가하고 overnight 정치한 후 믹서기로 조분쇄하고 90℃에서 2시간 열수 추출 하였다. 추출물은 동량의 glycerin을 가한 후 여과 천으로 여과하여 사용하였다. The materials used were crust, a dried mature tangerine. 100 g of the material was added with 10 times the weight of the dry weight, and the mixture was pulverized with a blender and subjected to hot water extraction at 90 ° C for 2 hours. The extracts were filtered with an equal volume of glycerin and filtered.
실시예Example 1: 탱자의 1: Taja's 페니실리움Penicillium 발효 추출물 제조 Fermented extract preparation
비교예 1과 같은 건조된 완숙 탱자인 지각을 사용하였다. 재료 100g에 건조중량대비 0.5배수 물을 가하고 미리 전배양한 페니실리움 종균(Penicillium oxalicum)을 1 ml 접종하고 25℃에서 3일간 배양하였다. 발효후 초기 건조중량대비 10배수 물을 가하고 동량의 glycerin을 가한 후 여과 천으로 여과하여 사용하였다. The crust, which was the dried mature tangerine as in Comparative Example 1, was used. 100 g of the material was added with 0.5 w / w of dry weight, and pre-pre-cultured Penicillium oxalicum ) and incubated at 25 ° C for 3 days. After the fermentation, 10 times more water was added to the initial dry weight, and the same amount of glycerin was added thereto, followed by filtration through a filter cloth.
실시예Example 2: 탱자의 유산균 발효 추출물 제조 2: Preparation of fermented extract of lactic acid bacteria from tangerine
비교예 1과 같은 건조된 완숙 탱자인 지각을 사용하였다. 재료 100g에 건조중량대비 10배수 물을 가하고 overnight 정치한 후 믹서기로 조분쇄하고 멸균한 후, 미리 전배양한 유산균 종균(Lactobacillus bulgaricus)을 1 ml 접종하고 30℃에서 2일간 배양하였다. 발효후 동량의 glycerin을 가한 후 여과 천으로 여과하여 사용하였다.The crust, which was the dried mature tangerine as in Comparative Example 1, was used. 100 g of the material was added to 10 g of dry weight, and the mixture was pulverized with a blender and sterilized. Then, 1 ml of lactobacillus bulgaricus pre-cultured was inoculated and cultured at 30 ° C for 2 days. After the fermentation, the same amount of glycerin was added and filtered through a filter cloth.
실시예Example 3: 탱자의 2단계 발효 추출물 제조 3: Manufacture of tangerine's 2 stage fermented extract
비교예 1과 같은 건조된 완숙 탱자인 지각을 사용하였다. 실시예 1와 같이, 재료 100g에 건조중량대비 0.5배수 물을 가하고 미리 전배양한 페니실리움 종균(Penicillium oxalicum)을 1 ml 접종하고 25℃에서 3일간 배양하였다. 발효후 실시예 2과 같이 미리 전배양한 유산균 종균(Lactobacillus bulgaricus)을 1 ml 접종하고 30℃에서 2일간 배양하였다. 발효후 동량의 glycerin을 가한 후 여과 천으로 여과하여 사용하였다.The crust, which was the dried mature tangerine as in Comparative Example 1, was used. As in Example 1, 0.5 g of dry weight was added to 100 g of the material, and 1 ml of pre-cultured Penicillium oxalicum was inoculated and cultured at 25 캜 for 3 days. After fermentation, Lactobacillus ( Lactobacillus sp. bulgaricus ) and incubated at 30 ° C for 2 days. After the fermentation, the same amount of glycerin was added and filtered through a filter cloth.
실험예Experimental Example
실험예 1: 확산법에 의한 항균 효능 평가Experimental Example 1: Evaluation of antimicrobial activity by diffusion method
상기 비교예 1 및 실시예 1 ~ 3에서 얻어진 추출물의 식중독균에 대한 항균 활성 스펙트럼을 조사하기 위해 1차 항균 활성으로서 한천 확산법을 통해 항균 활성을 측정하였다. 식중독균으로서 대장균(Escherichia coli), 바실러스 세레우스(Bacillus cereus)는 각각 Nutrient agar에, 황색포도상구균(Staphylococcus aureus), 비브리오균(Vibrio parahaemolyticus), 살모넬라균(Salmonella enteritidis)는 trypticase soy agar에, 캄필로박터균(Campylobacter jejuni)은 Brucella agar에, 리스테리아균(Listeria monocytogenes)은 Brain heart infusion agar에 배양하였다. 장내 유익균인 유산균은 비피도박테리움 롱굼(Bifidobacterium longum), 락토바실러스 불가리쿠스(Lactobacillus bulgaricus)는 각각 MRS agar 배지에서 배양하였다. 혐기성이 필요한 유산균 등은 anaerobic jar (Gaspak 첨가)을 이용하여 밀봉한 후, 37℃의 배양기에서 배양하였다. The antimicrobial activity of the extracts obtained in Comparative Example 1 and Examples 1 to 3 was measured by the agar diffusion method as the primary antimicrobial activity in order to examine the antimicrobial activity spectrum against the food poisoning bacteria. As food poisoning bacteria Escherichia coli), Bacillus cereus (Bacillus cereus), the Staphylococcus aureus (Staphylococcus aureus), Vibrio bacteria (Vibrio parahaemolyticus), Salmonella (Salmonella enteritidis) is on trypticase soy agar, Campylobacter bacteria (Campylobacter jejuni each Nutrient agar ) Were grown on Brucella agar, Listeria monocytogenes ) were cultured in Brain heart infusion agar. Bifidobacterium longum and Lactobacillus bulgaricus were cultured on MRS agar medium, respectively. Lactic acid bacteria that require anaerobic activity were sealed with an anaerobic jar (Gaspak added) and cultured in an incubator at 37 ° C.
여러 개의 원반 여과지에 기지농도의 추출물 용해액을 묻혀 시험균주가 도포된 고체 한천배지에 올려놓고 배양한 후 원반 주변의 투명대(growth inhibition halo)의 크기를 측정하였다. 이때 투명대가 클수록 항균 활성이 강한 것을 나타내며, 얻어진 결과를 하기 표 1에 나타내었다. 식중독균과 유산균 억제에 대한 대조군으로서는 항균보존료로 널리 사용되는 메틸 파라벤(methyl-paraben) 0.5% 용액을 사용하였다. 확산법에 의한 항균활성의 대표적인 예로 대장균에 대한 항균활성의 그림을 도 1에 나타내었다.The size of growth inhibition halo around the discs was measured after placing the test substance on the solid agar medium coated with the test solution by dissolving the extract solution at a predetermined concentration in several disc filters. At this time, the larger the zipper, the stronger the antibacterial activity, and the obtained results are shown in Table 1 below. A 0.5% solution of methyl-paraben, which is widely used as an antimicrobial preservative, was used as a control for the inhibition of food poisoning bacteria and lactic acid bacteria. A representative example of antimicrobial activity by the diffusion method is shown in FIG. 1, which is an illustration of the antimicrobial activity against E. coli.
[표 1] 확산법에 의한 추출물의 항균 활성 [Table 1] Antimicrobial activity of extracts by diffusion method
(투명대 크기 : -; 0mm, +; ∼5mm, ++; 6∼10mm, +++; 11∼15mm, ++++; 15∼20mm, +++++; 20∼ mm)10-15 mm, +++; 11-15 mm, ++++; 15-20 mm, +++++; 20 mm)
상기 표 1에 나타낸 바와 같이, 탱자(지각)의 단순 물추출물인 비교예 1 추출물의 경우에는 그람음성균인 대장균, 비브리오균, 살모넬라균 등에 대해 약간의 효과가 있었으나 그람양성균에 대해서는 효과가 그리 크지 않았다. 페니실리움이 발효하여 과피조직이 분해된 실시예 1 추출물의 경우에는 비교예 1 보다 증가된 항균성을 나타내었으며, 유산균만을 발효시켜 추출한 실시예 2 추출물의 경우에는 비교예 1 보다는 항균력이 증가하였지만 실시예 1와 비교해서는 큰 차이를 나타내지 않았다. 반면 2단계 발효에 의한 추출물인 실시예 3 추출물의 경우에는 같은 농도에서 비교예 1, 실시예 1 및 2에 비해 상당히 향상된 항균력을 나타내었다. 이는 일반적으로 사용되는 항균보존료인 파라벤에 비해서도 우수한 것이었다. 이렇게 항균력이 증진된 결과는 2단계 발효의 첫 번째 발효에서 페니실리움균의 작용에 의해 식물조직이 분해되어 식물의 생리활성 성분의 용출이 용이해지고 저분자화된 때문으로 추정되며 또한 이어진 발효에서 유산균 발효에 의해 식물의 페놀 성분 등 항균 성분이 활성구조 또는 미생물 세포에 침투되기 쉬운 저분자 구조로 변환되는 등의 시너지(synergy)효과인 것으로 판단된다. 또 이렇게 항균력이 증가되었음에도 상대적으로 비피더스 및 락토바실러스 등 유산균에 대한 항균성은 크게 증가하지 않은 것은 두 번째 유산균 발효를 통해 유산균에 크게 유해하지 않은 조성이 이루어졌기 때문으로 추정된다. As shown in Table 1, the extract of Comparative Example 1, which is a simple water extract of Tanger (crustacean), had some effects on Gram-negative bacteria such as Escherichia coli, Vibrio bacteria, Salmonella bacteria and the like but the effect on Gram positive bacteria was not significant . The extract of Example 1, in which the phencyclium fermented and the pericarp was degraded, showed increased antimicrobial activity compared to Comparative Example 1. In the case of Example 2 extract obtained by fermenting only lactic acid bacteria, the antibacterial activity was increased compared to Comparative Example 1, But did not show a large difference compared to Example 1. On the other hand, the extract of Example 3, which is an extract from the two-stage fermentation, exhibited significantly improved antibacterial activity at the same concentration as Comparative Example 1 and Examples 1 and 2. This was superior to parabens, a commonly used antimicrobial preservative. The result of this enhancement of antibacterial activity is presumed to be due to decomposition of plant tissue by the action of penicillium bacterium in the first fermentation of the second stage fermentation, facilitating the elution of physiologically active components of the plant and becoming low molecular weight, It is believed that the fermentation is a synergy effect such that the antimicrobial component such as the phenol component of the plant is converted into an active structure or a low molecular structure which is likely to be infiltrated into microbial cells. In addition, antimicrobial activity against lactic acid bacteria such as bifidus and lactobacillus was not significantly increased even though the antimicrobial activity was increased. It is presumed that the second lactic acid fermentation resulted in a composition which was not harmful to the lactic acid bacteria.
실험예Experimental Example 2: 액체배양법에 의한 식중독균에 대한 최소 억제 농도 ( 2: Minimum inhibitory concentration on food poisoning bacteria by liquid culture method MICMIC ) 결정) decision
본 발명에 따른 조성물의 최소저해농도 (Minimum Inhibition Concentration: MIC)를 측정하기 위해 하기와 같이 수행하였다. 대상 균주들을 실험예 1의 배양배지에서 agar를 뺀 배양배지를 사용하여 전배양한 후, 시료를 배지에 serial dilution하여 준비하고, 전배양한 균액을 약 107 cell/ml이 되도록 접종하였다. 각각의 배양조건에서 배양한 후 미생물 증식 여부를 확인하여, 균이 증식되지 않는 최소 농도(고형분 함량으로 환산)를 MIC로 결정하였다. 식중독균과 유산균 억제에 대한 대조군으로서는 항균보존료로 널리 사용되는 메틸 파라벤(methyl-paraben) 0.5% 용액을 사용하였다. The minimum inhibition concentration (MIC) of the composition according to the present invention was measured as follows. The target strains were pre-cultured in a culture medium obtained by subtracting agar from the culture medium of Experimental Example 1, serial dilution of the sample was prepared in the medium, and the pre-cultured broth was inoculated at about 10 7 cells / ml. After culturing in each culture condition, microbial growth was confirmed, and the minimum concentration (in terms of solid content) at which the microorganism did not grow was determined as MIC. A 0.5% solution of methyl-paraben, which is widely used as an antimicrobial preservative, was used as a control for the inhibition of food poisoning bacteria and lactic acid bacteria.
[표 2] 액체배양법 의한 식물 추출물의 최소억제농도(MIC, 단위 ppm) [Table 2] Minimum inhibitory concentration (MIC, unit ppm) of plant extract by liquid culture method
상기 표 2에 나타낸 바와 같이, 탱자(지각)의 단순 물추출물인 비교예 1 추출물의 경우에는 전체적으로 그람음성균인 대조군에 비해 비교적 높은 MIC 결과치를 나타내었다. 확산법에서의 결과와 마찬가지로 실시예 1 추출물의 경우에는 비교예 1 보다 증가된 항균성을 나타내었으며, 실시예 2 추출물의 경우에는 비교예 1 보다는 항균력이 증가하였지만 실시예 1와 비교해서는 큰 차이를 나타내지 않았다. 반면 2단계 발효에 의한 추출물인 실시예 3 추출물의 경우에는 같은 농도에서 비교예 1, 실시예 1 및 2에 비해 상당히 향상된 항균력, 즉 적은 MIC 결과치를 나타내었으며 대조군인 파라벤에 비해서도 우수한 것이었다. 또 확산법에서의 결과와 마찬가지로 유산균에 대한 항균성은 크게 증가하지 않았다. As shown in the above Table 2, the extract of Comparative Example 1, which is a simple water extract of Tajia (crust), showed a relatively high MIC result as compared with the control group of Gram-negative bacteria. As in the case of the diffusion method, the extract of Example 1 showed an increased antimicrobial activity than that of Comparative Example 1, and the extract of Example 2 showed an increase in the antibacterial activity compared with Comparative Example 1, . On the other hand, the extract of Example 3, which is an extract from the two-stage fermentation, exhibited significantly improved antibacterial activity, i.e., a small MIC value, as compared with Comparative Example 1 and Examples 1 and 2, and was superior to the control paraben. In addition, the antimicrobial activity against lactic acid bacteria was not significantly increased as in the diffusion method.
실험예Experimental Example 3 : 여드름균에 대한 항균 활성 3: Antimicrobial activity against acne bacteria
피부서식 세균 중 여드름의 원인균인 프로피오니박테리움 아크네(Propionibacterium acne)에 대한 항균 활성을 측정하여 얻어진 결과를 하기 표 3, 4에 나타내었다. 여드름 균은 Reinforced Clostridial Medium과 Brain Heart Infusion Medium에 0.1% Tween 80을 첨가한 배지를 사용하였으며, anaerobic jar (Gaspak 첨가)을 이용하여 밀봉한 후, 37℃의 배양기에서 3일 동안 배양하였다. 여드름균 억제에 대한 대조군으로서는 5% benzoyl peroxide을 사용하였다. The results obtained by measuring the antimicrobial activity against Propionibacterium acne , a causative organism of acne among skin-forming bacteria, are shown in Tables 3 and 4. Acne bacteria were cultured in a Reinforced Clostridial Medium and a Brain Heart Infusion Medium supplemented with 0.1% Tween 80, sealed with an anaerobic jar (Gaspak), and incubated in a 37 ° C incubator for 3 days. 5% benzoyl peroxide was used as a control for acne inhibition.
[표 3] 확산법에 의한 추출물의 여드름균에 대한 항균 활성 [Table 3] Antimicrobial activity of extracts against acne bacteria by diffusion method
(투명대 크기 : -; 0mm, +; ∼5mm, ++; 6∼10mm, +++; 11∼15mm, ++++; 15∼20mm, +++++; 20∼ mm)10-15 mm, +++; 11-15 mm, ++++; 15-20 mm, +++++; 20 mm)
[표 4] 여드름균에 대한 추출물의 최소억제농도(MIC, 단위 ppm) [Table 4] Minimum inhibitory concentration (MIC, in ppm) of extracts against acne bacterium
상기 표 3, 4에 나타낸 바와 같이, 여드름균에 대해서 비교예 1 추출물의 경우에는 매우 약한 항균성으로 판단되었으며, 실시예 1와 2 추출물의 경우에는 비교예 1 보다는 항균력이 좋아 대조군과 유사한 항균성을 나타내었다. 반면 2단계 발효에 의한 추출물인 실시예 3 추출물의 경우에는 같은 농도에서 비교예 1, 실시예 1 및 2에 비해 상당히 향상된 항균력, 즉 큰 저해환 형성과 적은 MIC 결과치를 나타내었으며 대조군에 비해서도 매우 우수한 것이었다.As shown in Tables 3 and 4, the extracts of Comparative Example 1 were found to have very weak antimicrobial activity against acne bacteria, whereas the extracts of Examples 1 and 2 showed better antibacterial activity than Comparative Example 1, . On the other hand, the extract of Example 3, which is an extract from the two-stage fermentation, exhibited significantly improved antibacterial activity at the same concentration as Comparative Example 1 and Examples 1 and 2, namely, formation of large inhibitory rings and low MIC results. .
상기 확산법과 MIC 측정법 결과를 참조하면, 본 발명에 따른 조성물은 여드름균에 대해서도 높은 항균 활성을 나타냄을 알 수 있다. Referring to the results of the diffusion method and the MIC measurement method, it can be seen that the composition according to the present invention exhibits a high antibacterial activity against acne bacteria.
실험예Experimental Example 4: 비듬균에4: To staminate 대한 항균 활성 Antimicrobial activity against
비듬균에 대한 항균성을 알아보기 위하여 피티로스포룸 오발(Pityrosporum ovale)을 사용하여 균 성장 억제를 측정하였으며, 얻어진 결과를 하기 표 5, 6에 나타내었다. 비듬균은 피티로스포룸 배지(Malt Extract 6%, Ox-bile 2%, Tween 40 1%, Glycerol mono-oleae 0.25%)를 사용하여 배양하였다. 비듬균 억제에 대한 대조군으로서는 이타코나졸(itaconazole) 0.2%를 사용하였다.To investigate the antimicrobial activity against dandruff, Pityrosporum ovale ), and the results obtained are shown in Tables 5 and 6 below. The dandruff was cultured using a Petit rosporum medium (Malt Extract 6%, Ox-bile 2%, Tween 40 1%, Glycerol mono-oleate 0.25%). 0.2% of itaconazole was used as a control group against dandruff.
[표 5] 확산법에 의한 추출물의 비듬균에 대한 항균 활성 [Table 5] Antimicrobial activity of extracts on dandruff by diffusion method
(투명대 크기 : -; 0mm, +; ∼5mm, ++; 6∼10mm, +++; 11∼15mm, ++++; 15∼20mm, +++++; 20∼ mm)10-15 mm, +++; 11-15 mm, ++++; 15-20 mm, +++++; 20 mm)
[표 6] 비듬균에 대한 추출물의 최소억제농도(MIC, 단위 ppm) [Table 6] Minimum inhibitory concentration (MIC, in ppm) of extracts against dicobacteria
상기 표 5, 6에 나타낸 바와 같이, 비듬균에 대해서 비교예 1 추출물의 경우에는 매우 약한 항균성으로 판단되었으며, 실시예 1와 2 추출물의 경우에는 비교예 1 보다는 항균력이 좋아 대조군과 유사한 항균성을 나타내었다. 반면 2단계 발효에 의한 추출물인 실시예 3 추출물의 경우에는 같은 농도에서 비교예 1, 실시예 1 및 2에 비해 상당히 향상된 항균력, 즉 큰 저해환 형성과 적은 MIC 결과치를 나타내었으며 대조군에 비해서도 매우 우수한 것이었다. As shown in Tables 5 and 6, the extract of Comparative Example 1 had very weak antimicrobial activity against dandruff, and the extracts of Examples 1 and 2 showed better antibacterial activity than Comparative Example 1, . On the other hand, the extract of Example 3, which is an extract from the two-stage fermentation, exhibited significantly improved antibacterial activity at the same concentration as that of Comparative Example 1 and Examples 1 and 2, namely, formation of large inhibitory rings and low MIC results. .
상기 확산법과 MIC 측정법 결과를 참조하면, 본 발명에 따른 조성물은 비듬균에 대해서도 비교적 높은 항균 활성을 나타냄을 알 수 있다. Referring to the results of the diffusion method and the MIC measurement method, it can be seen that the composition according to the present invention shows a relatively high antibacterial activity against dicobacteria.
실험예Experimental Example 5: 페놀성 성분의 함량 및 항산화 효과 5: Contents and antioxidant effect of phenolic components
각 추출물의 페놀성화합물의 양과 항산화력을 측정하였다. 총 폴리페놀의 함량은 다음과 같은 방법에 의해 측정하였다. 즉 추출조건에 따라 제조된 추출물을 희석한 후, 희석액 5 ml에 folin reagent 5 ml를 가하고 5분간 정치시킨 다음 5 ml의 10% sodium carbonate 용액을 가하였다. 이 혼합액을 1시간 동안 정치한 다음 분광광도계(UV/Vis Spectrophotometer)를 사용하여 760 nm에서 흡광도를 측정하고 (+)catechin을 이용하여 작성한 표준곡선으로부터 총 폴리페놀 함량을 구하였다. 한편 전자 공여작용(elctron donating activity)에 의한 항산화 활성 측정은 DPPH와 같은 안정한 자유 라디칼을 이용하여 LOO 의 model계에서 radical에 대한 항산화물질의 반응성을 라디칼의 감소량이나 감소 속도로부터 직접 평가하는 방법이다. 전자 공여작용은 각 시료 0.2 ml에 4x10-4 M DPPH 용액 (2,2'-diphenyl-picrylhydrazyl)을 첨가한 후 10초간 진탕하고 10분 후 분광광도계(UV/VIS spectrophotometer)를 사용하여 525nm에서 흡광도를 측정하였다. 이때 전자공여 효과는 시료 첨가구와 시료 무첨가군의 흡광도 차이를 백분율로 계산하였다. 폴리페놀 함량과 항산화 활성의 결과는 아래 표 7에 나타내었다.The amount of phenolic compounds and the antioxidant capacity of each extract were measured. The total polyphenol content was measured by the following method. 5 ml of the folin reagent was added to the diluted solution, and the mixture was allowed to stand for 5 minutes. Then, 5 ml of 10% sodium carbonate solution was added thereto. After the mixture was allowed to stand for 1 hour, the absorbance was measured at 760 nm using a spectrophotometer (UV / Vis Spectrophotometer) and the total polyphenol content was determined from a standard curve prepared using (+) catechin. On the other hand, the antioxidant activity by elctron donating activity is directly evaluated from the decrease or decrease rate of radicals in the LOO model system by using stable free radical such as DPPH. The electron donating activity was measured by adding a 4 x 10 -4 M DPPH solution (0.22 g) to each sample (0.2 ml), shaking for 10 seconds, and then measuring the absorbance at 525 nm using a spectrophotometer (UV / VIS spectrophotometer) Were measured. At this time, the electron donating effect was calculated as a percentage difference between the absorbance of the sample and the sample without addition. The results of polyphenol content and antioxidant activity are shown in Table 7 below.
[표 7] 항산화 활성[Table 7] Antioxidant activity
(0.1 mg/ml)Control group: Vitamin C
(0.1 mg / ml)
상기 표 7을 참조하면, 실시예 3 추출물의 폴리페놀 함량 및 항산화력의 수치가 단순추출인 비교예 1 및 단일 발효인 실시예 1, 2 추출물에 비해 월등히 높은 것으로 알 수 있다. 실시예 3 추출물은 전술한 바의 실험 결과에 나타난 바와 같이 식중독균, 피부유해 상재균에 대한 항균 활성이 우수할 뿐만 아니라 항산화능이 있어 식품, 화장품, 생활용품 등의 조성물로서 활용가능한 성분인 것으로 확인되었다. Referring to Table 7, it can be seen that the polyphenol content and antioxidant power of the extract of Example 3 are significantly higher than those of Comparative Example 1, which is a simple extract, and Extract 1 and 2, which are single fermented. The extract of Example 3 was found to be a useful component as a composition for foods, cosmetics, daily necessities and the like, which is excellent in antimicrobial activity against food poisoning bacteria and skin harmful fungi, as well as has antioxidant ability, as shown in the above- .
이하, 제형예 1 ~ 3을 들어 상기 실시예 3에서 제조된 추출물을 포함하는 식품, 화장품, 스프레이 제품의 조성물 구성을 보다 구체적으로 설명한다. 그러나 본 발명의 조성물이 이들 제형예에 한정되는 것은 아니다.Hereinafter, the compositions of the foods, cosmetics, and spray products containing the extract prepared in Example 3 will be described in more detail with reference to Formulation Examples 1 to 3. However, the composition of the present invention is not limited to these formulation examples.
제형예Formulation Example 1. 식품(음료) 조성물 1. Food (beverage) composition
제형예Formulation Example 2. 화장품 ( 2. Cosmetics ( 밀크로션Milk lotion ) 조성물) Composition
제형예Formulation Example 3. 스프레이(주방기구 살균용)3. Spray (for sterilization of kitchen utensils) 조성물 Composition
Claims (15)
The method according to any one of claims 2 to 5, wherein the lactic acid bacterium is selected from the group consisting of a Bifidobacterium sp strain containing Bifidobacterium longum and a Lactobacillus bulgaricus strain Lt; RTI ID = 0.0 > 1, < / RTI >
A method for producing an antimicrobial composition, which comprises fermenting a panacea extract with Penicillium.
Wherein the extract is fermented with a lactic acid bacterium to produce an antimicrobial composition.
상기 1차 발효물에 1:1 ~ 1: 10의 비율로 비율로 물을 가하는 단계; 및
상기 물이 가여진 1차 발효물에 전배양한 유산균 균주를 접종하고, 15 ~ 40 ℃, 0.5 ~ 5 일 동안 2차 발효하는 단계를 포함하는 항균 조성물 제조 방법. 10. The method according to claim 9, wherein water is added at a ratio of 1: 1 to 1: 0.1 based on the dry weight of the panther extract, and the Penicillium strain pre-cultured in the water extract- 1 < / RTI > for 1 to 10 days at 30 DEG C;
Adding water to the primary fermentation product at a ratio of 1: 1 to 1:10; And
A step of inoculating a lactic acid bacterium strain pre-cultured in the primary fermentation product added with water and secondary fermentation at 15 to 40 DEG C for 0.5 to 5 days.
4. The antimicrobial composition according to any one of claims 1 to 3, wherein the composition is a food, cosmetic or spray disinfectant containing from 0.1 to 50% by weight of fermented turmeric extract.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160075249A KR101943153B1 (en) | 2016-06-16 | 2016-06-16 | Composition comprising fermented Poncirus trifoliata extract with antimicrobial and antiseptic activity and methods of preparation thereof |
KR1020180130289A KR102313373B1 (en) | 2016-06-16 | 2018-10-29 | Composition comprising fermented Poncirus trifoliata extract with both of antimicrobial and antifungal activity and methods of preparation thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160075249A KR101943153B1 (en) | 2016-06-16 | 2016-06-16 | Composition comprising fermented Poncirus trifoliata extract with antimicrobial and antiseptic activity and methods of preparation thereof |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020180130289A Division KR102313373B1 (en) | 2016-06-16 | 2018-10-29 | Composition comprising fermented Poncirus trifoliata extract with both of antimicrobial and antifungal activity and methods of preparation thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20170142040A true KR20170142040A (en) | 2017-12-27 |
KR101943153B1 KR101943153B1 (en) | 2019-04-17 |
Family
ID=60938861
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020160075249A KR101943153B1 (en) | 2016-06-16 | 2016-06-16 | Composition comprising fermented Poncirus trifoliata extract with antimicrobial and antiseptic activity and methods of preparation thereof |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101943153B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102202092B1 (en) * | 2019-10-18 | 2021-01-12 | 한국엔디랩 주식회사 | Weissella koreensis nd824 strain having improved productivity of ornithine and composition comprisingng the same |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20040019116A (en) * | 2002-08-21 | 2004-03-05 | 주식회사 렉스진바이오텍 | Fermented extract of a fruit of the trifoliate orange, and a composition for treating the disease caused by infection of helicobacter pylori |
KR20130121600A (en) * | 2012-04-27 | 2013-11-06 | 중앙대학교 산학협력단 | Extract of fruit of poncirus sp. and/or gardenia sp. having antimicrobial activity and composition comprising thereof |
KR20140017933A (en) * | 2012-08-02 | 2014-02-12 | 동아대학교 산학협력단 | Composition comprising fermented extract of trifoliate orange for improving diabetes |
KR20140017932A (en) * | 2012-08-02 | 2014-02-12 | 동아대학교 산학협력단 | Composition of diabetes-improving effective constituents by fermentation products of the trifoliate orange |
KR20160015988A (en) * | 2014-08-01 | 2016-02-15 | 경희대학교 산학협력단 | Composition for the prevention or treatment of periodontal disease comprising extract of Fermented Ponciri Fructus |
-
2016
- 2016-06-16 KR KR1020160075249A patent/KR101943153B1/en active IP Right Grant
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20040019116A (en) * | 2002-08-21 | 2004-03-05 | 주식회사 렉스진바이오텍 | Fermented extract of a fruit of the trifoliate orange, and a composition for treating the disease caused by infection of helicobacter pylori |
KR20130121600A (en) * | 2012-04-27 | 2013-11-06 | 중앙대학교 산학협력단 | Extract of fruit of poncirus sp. and/or gardenia sp. having antimicrobial activity and composition comprising thereof |
KR20140017933A (en) * | 2012-08-02 | 2014-02-12 | 동아대학교 산학협력단 | Composition comprising fermented extract of trifoliate orange for improving diabetes |
KR20140017932A (en) * | 2012-08-02 | 2014-02-12 | 동아대학교 산학협력단 | Composition of diabetes-improving effective constituents by fermentation products of the trifoliate orange |
KR20160015988A (en) * | 2014-08-01 | 2016-02-15 | 경희대학교 산학협력단 | Composition for the prevention or treatment of periodontal disease comprising extract of Fermented Ponciri Fructus |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102202092B1 (en) * | 2019-10-18 | 2021-01-12 | 한국엔디랩 주식회사 | Weissella koreensis nd824 strain having improved productivity of ornithine and composition comprisingng the same |
Also Published As
Publication number | Publication date |
---|---|
KR101943153B1 (en) | 2019-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101532005B1 (en) | Natural preservative comprising citrus junos seed extract and manufacturing method thereof | |
KR101068151B1 (en) | Composition comprising of plant extract having antimicrobial and antiseptic activity and the use thereof | |
CN106070538A (en) | A kind of biogenic seafood nourishing antistaling agent | |
CN104958248A (en) | Biological antibacterial composition and application of biological antibacterial composition in cosmetics | |
KR20130074983A (en) | Composition of preservatives for cosmetic and cosmetic composition comprising the same | |
KR101780863B1 (en) | Cosmetic Composion for Acne Improvement Containing Butanol Fraction of Red Ginseng Ethanol Extract | |
Parseh et al. | Antimicrobial properties of Pomegranate (Punica granatum L.) as a Tannin rich Fruit | |
KR101483749B1 (en) | Whitening cosmetic composition and Antibacterial composition containing the extract of Hippophae rhamnoides L. | |
KR102313373B1 (en) | Composition comprising fermented Poncirus trifoliata extract with both of antimicrobial and antifungal activity and methods of preparation thereof | |
CN110521763A (en) | A kind of seawater fish bio-preservative and its preparation and application | |
KR20090075282A (en) | Cosmetic composition for the natural preservative from decay containing the extract of the chopi | |
KR101465696B1 (en) | Antibacterial and insect resistance composition | |
KR101602552B1 (en) | Antimicrobial composition comprising the extract of cornus officinalis | |
KR20120061221A (en) | COMPOSITION OF NURAL EXTRACT, JAPANESE SUMAC AND ANEMARRHENA RHIZOME AND Ailanthus altissima AND THEIR USE | |
KR101943153B1 (en) | Composition comprising fermented Poncirus trifoliata extract with antimicrobial and antiseptic activity and methods of preparation thereof | |
KR102163969B1 (en) | Cosmetic Compositions Containing Fermented Extracts of Vernicia fordii | |
KR101911847B1 (en) | Antimicrobial composition comprising organic solvent fractions of arctium lappa root extracts as an effective component | |
KR101063351B1 (en) | The extracts and fractions of Hippophae rhamnoides L. | |
KR102117693B1 (en) | Complex natural antibacterial agent containing rosemary, cinnamon and fatty acid and method for preparing the same | |
CN106344453A (en) | Novel acne cream and preparation method thereof | |
KR20210007577A (en) | Antimicrobial composition comprising Morus alba bark extract, Brussels sprout extract, Soapberry extract and Angelica keiskei extract | |
KR20110120481A (en) | Natural preservative cosmetic composition containing fermented liquor of kimchi lactic acid bacteria and extract of willow bark as antibacterial ingredient | |
KR20090046387A (en) | Functional cosmetic composition comprising scutellaria,houttuynia,artemisia,citurs junos extract having antimicrobial activity | |
KR102196276B1 (en) | Probiotic composition comprising green tea fermented extract having antibacterial activity against acne-causing resident skin flora and antioxidant efficacy | |
KR100787634B1 (en) | Cosmetic composition having antiseptic activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
A107 | Divisional application of patent | ||
AMND | Amendment | ||
X701 | Decision to grant (after re-examination) | ||
GRNT | Written decision to grant |